The AI Revolution In Multivigilance

By Bruce Palsulich, Vice President, Product Strategy

The life science industry is undergoing dynamic change thanks to advances in science and engineering. Companies are developing, testing, and marketing medicines based on new technologies that promise to treat everything from cancer to rare genetic conditions more effectively than ever. At the same time, the costs of R&D have exploded. Bringing a therapy from the lab through approvals takes more than a decade, on average, at an overall investment of more than $2.6 billion, according to industry estimates.